May 14 () - EyePoint said on Thursday an independent safety committee found no new concerns in two late-stage trials of its experimental eye disease drug Duravyu and recommended the studies continue ...
Many common conditions linked to aging develop without symptoms for years. Learn which five pose the biggest risks and the ...
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, ...
LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...
Ocular Therapeutix, Inc. ( OCUL) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDT Ocular Therapeutics. Presenting for Ocular today and sitting up on stage with me is Dr.
Researchers have identified distinct biological features linked to a high risk of developing a severe form of age-related ...
Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.
In an observational claims database, patients using GLP-1 receptor agonists (GLP-1RAs) had significantly lower risk of ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
Purpose The cross-sectional and longitudinal associations between accelerated biological ageing and the risk of cataract and ...
According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results